News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
690,000 Results
Type
Article (39292)
Company Profile (282)
Press Release (650426)
Section
Business (204093)
Career Advice (2000)
Deals (35400)
Drug Delivery (89)
Drug Development (80985)
Employer Resources (168)
FDA (16130)
Job Trends (14824)
News (345024)
Policy (32486)
Tag
Academia (2534)
Alliances (49348)
Alzheimer's disease (1283)
Approvals (16091)
Artificial intelligence (160)
Bankruptcy (354)
Best Places to Work (11597)
Biotechnology (199)
Breast cancer (201)
Cancer (1489)
Cardiovascular disease (119)
Career advice (1666)
Cell therapy (307)
Clinical research (64991)
Collaboration (552)
Compensation (302)
COVID-19 (2548)
C-suite (130)
Data (1459)
Diabetes (185)
Diagnostics (6191)
Earnings (85013)
Employer resources (146)
Events (110344)
Executive appointments (459)
FDA (16882)
Funding (501)
Gene therapy (213)
GLP-1 (620)
Government (4340)
Healthcare (18742)
Infectious disease (2644)
Inflammatory bowel disease (112)
Interviews (309)
IPO (16377)
Job creations (3634)
Job search strategy (1419)
Layoffs (425)
Legal (7876)
Lung cancer (220)
Manufacturing (214)
Medical device (13228)
Medtech (13233)
Mergers & acquisitions (19259)
Metabolic disorders (487)
Neuroscience (1634)
NextGen: Class of 2025 (6507)
Non-profit (4472)
Northern California (1848)
Obesity (278)
Opinion (188)
Parkinson's disease (105)
Patents (130)
People (56628)
Phase I (20213)
Phase II (28600)
Phase III (21332)
Pipeline (602)
Postmarket research (2589)
Preclinical (8554)
Radiopharmaceuticals (238)
Rare diseases (281)
Real estate (5902)
Regulatory (21778)
Research institute (2313)
Resumes & cover letters (349)
Southern California (1591)
Startups (3570)
United States (16363)
Vaccines (572)
Weight loss (192)
Date
Today (126)
Last 7 days (870)
Last 30 days (2136)
Last 365 days (35044)
2025 (1346)
2024 (35263)
2023 (40091)
2022 (51184)
2021 (55728)
2020 (54100)
2019 (46571)
2018 (35041)
2017 (32145)
2016 (31493)
2015 (37591)
2014 (31366)
2013 (26411)
2012 (28621)
2011 (29304)
2010 (27363)
Location
Africa (717)
Arizona (202)
Asia (37398)
Australia (6107)
California (4173)
Canada (1531)
China (352)
Colorado (188)
Connecticut (199)
Europe (80352)
Florida (587)
Georgia (141)
Illinois (409)
Indiana (237)
Maryland (673)
Massachusetts (3230)
Michigan (180)
Minnesota (312)
New Jersey (1170)
New York (1186)
North Carolina (777)
Northern California (1848)
Ohio (150)
Pennsylvania (985)
South America (1094)
Southern California (1591)
Texas (600)
Utah (118)
Washington State (425)
690,000 Results for "boehringer ingelheim vetmedica inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals
On Thursday, Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.
January 10, 2025
·
2 min read
·
Tristan Manalac
Biosimilars
Boehringer Ingelheim Partners With GoodRx to Offer Humira Biosimilar at 92% Discount
In a bid to take advantage of Humira’s slow loss of market share, Boehringer Ingelheim is offering its biosimilar at a 92% discount exclusively to patients who buy the product on GoodRx.
July 19, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
January 9, 2025
·
3 min read
Legal
Boehringer Ingelheim Loses Legal Challenge to IRA in Connecticut Federal Court Ruling
A federal judge ruled last week that the U.S. government can use its economic standing as a bulk purchaser to negotiate for better deals, handing Boehringer Ingelheim a loss in its legal challenge to the Inflation Reduction Act.
July 8, 2024
·
2 min read
·
Tristan Manalac
Business
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.
May 2, 2024
·
6 min read
Business
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut.
May 16, 2024
·
3 min read
Business
PhoreMost Achieves Second Milestone in Target Discovery Alliance with Boehringer Ingelheim
PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim.
June 3, 2024
·
2 min read
Press Releases
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale
January 8, 2025
·
6 min read
Biotech Bay
Boehringer Ingelheim expands access to adalimumab-adbm injection, the company’s biosimilar to Humira®
Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s biosimilar to Humira®, in the U.S.
May 13, 2024
·
11 min read
Drug Development
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 7, 2024
·
7 min read
1 of 69,000
Next
